Title:
ESKETAMINE FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
Document Type and Number:
WIPO Patent Application WO/2021/038500
Kind Code:
A3
Abstract:
The disclosure relates to methods for reducing symptoms of major depressive disorder, including suicidality, in a human patient assessed to be at imminent risk for suicide comprising the administration of esketamine in addition to standard of care treatment. In certain embodiments, the methods comprise determining if the patient has previously attempted suicide, and, if so, treating such patient with a standard of care treatment and a therapeutically effective amount of esketamine, whereas patients determined not to have previously attempted suicide are administered standard of care treatment without treating the patient with esketamine.
More Like This:
Inventors:
CANUSO CARLA M (US)
FU DONG-JING (US)
IONESCU DAWN F (US)
LANE ROSEANNE (US)
FU DONG-JING (US)
IONESCU DAWN F (US)
LANE ROSEANNE (US)
Application Number:
PCT/IB2020/058030
Publication Date:
April 22, 2021
Filing Date:
August 28, 2020
Export Citation:
Assignee:
JANSSEN PHARMACEUTICALS INC (US)
International Classes:
A61K31/135; A61K45/06
Domestic Patent References:
| WO2019126108A1 | 2019-06-27 |
Foreign References:
| US20160338977A1 | 2016-11-24 | |||
| US20160074340A1 | 2016-03-17 | |||
| US20130236573A1 | 2013-09-12 |
Attorney, Agent or Firm:
SHIRTZ, Joseph F. et al. (US)
Download PDF:
Previous Patent: DISCHARGING CONTAINER
Next Patent: ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS
Next Patent: ISOXAZOLINE COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS